Polatuzumab Vedotin in Previously Untreated DLBCL: an Asia Subpopulation Analysis from the Phase 3 POLARIX Trial.
Yuqin Song,Herve Tilly,Shinya Rai,Huilai Zhang,Jie Jin,Hideki Goto,Yasuhito Terui,Ho-Jin Shin,Won Seog Kim,Junning Cao,Jifeng Feng,Hyeon Seok Eom,Tae Min Kim,Xavier Cheng-Hong Tsai,Jyh-Pyng Gau,Hideo Koh,Liling Zhang,Yongping Song,Yu Yang,Wei Li,He Huang,Kiyoshi Ando,Jeff P. Sharman,Laurie H. Sehn,Lilian Bu,Xin Wang,Yanwen Jiang,Jamie Hirata,Calvin Lee,Jun Zhu,Koji Izutsu
DOI: https://doi.org/10.1182/blood.2022017734
IF: 20.3
2023-01-01
Blood
Abstract:In the phase 3 POLARIX study in previously untreated diffuse large B-cell lymphoma, polatuzumab vedotin combined with rituximab plus cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) significantly improved progression-free survival (PFS) compared with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with similar safety. Patients were randomized 1:1 to 6 cycles of Pola-R-CHP or R-CHOP plus 2 cycles of rituximab alone. For registration of POLARIX in China, consistency of PFS in an Asia subpopulation (defined as >= 50% of the risk reduction in PFS expected in the global population) was evaluated. Overall, 281 patients were analyzed: 160 patients from Asia in the intention-to-treat (ITT) population of the global study and 121 from an ITT China extension cohort. Of these, 141 were randomized to Pola-R-CHP and 140 to R -CHOP. At data cutoff (28 June 2021; median follow-up 24.2 months), PFS met the con-sistency definition with the global population, and was superior with Pola-R-CHP vs R -CHOP (hazard ratio, 0.64; 95% confidence interval [CI], 0.40-1.03). Two-year PFS was 74.2% (95% CI, 65.7-82.7) and 66.5% (95% CI, 57.3-75.6) with Pola-R-CHP and R-CHOP, respectively. Safety was comparable between Pola-R-CHP and R-CHOP, including rates of grade 3 to 4 adverse events (AEs; 72.9% vs 66.2%, respectively), serious AEs (32.9% vs 32.4%), grade 5 AEs (1.4% vs 0.7%), AEs leading to study treatment discontinuation (5.0% vs 7.2%), and any-grade peripheral neuropathy (44.3% vs 50.4%). These findings demonstrate consistent efficacy and safety of Pola-R-CHP vs R-CHOP in the Asia and global populations in POLARIX. This trial was registered at https://clinicaltrials.gov/ct2/home as # NCT03274492.